The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
TCL
Vol.
34
No.
08
February 29, 2008
- PFS Is A Benefit “In The Right Context,” Pazdur Says In Q&A On Avastin Approval.
- Meta-Analysis Finds ESA Use In Oncology Associated With Increases In VTE, Mortality.
- Ohio Judge Fines CareToLive Prostate Cancer Group That Sought The Cancer Letter’s Confidential Source Material On Provenge.
- Levine, Mendelsohn Win Landon Awards; Ullrich Wins Pezcoller.
CCL
Vol.
31
No.
2
February 29, 2008
- Large Phase III Trial Seeks Optimal Use Of Tykerb vs. Herceptin In Breast Cancer
- Most Older Men With Early Prostate Cancer Can Avoid Treatment, Analysis Finds
- Extent Of Risk Reduction From Ovary Removal Varies According To BRCA Mutation
- Smoking Increases Breast Cancer Risk Based on Genes
- Larynx Preservation Provides Better Voice Quality For Patients
- PET Better At Evaluating Response In Sarcoma
- Sorafenib Targets AML Driven By Mutant FLT3 Gene
- NCI Cooperative Group, Cancer Center Trials Listed
TCL
Vol.
34
No.
09
March 07, 2008
- NCI R01 Payline Falls To 12th Percentile In Fifth Year Of No-Growth Budgets.
- Clinical Trials System “Slowly Unraveling,”
- ASCO’s Lichter Says. Dingell, Stupak Urge FDA To “Act With Due Haste To Avoid Endangering Patients” Steered To ESAs.
- Professional Groups Agree On Colon Cancer Screening Guidelines.
- Blayney Elected ASCO President For 2009.
- NIH Advisors Urge Overhaul Of Peer Review System.
TCL
Vol.
34
No.
10
March 14, 2008
TCL
Vol.
34
No.
11
March 21, 2008
- ODAC Meeting: Further Restrictions Likely On ESA Use; Changes Advocated by ODAC May Cut Market By 40-50 Percent.
- ODAC Member Critical Of Amgen For Price Incentives.
- Amgen, J&J Defend ESA Indications.
- ODAC Recommends Approval Of Nplate For Thrombocytopenia.
- Funding Opportunities: HHMI Commits $300M To Support Early Career Scientists.
CCL
Vol.
31
No.
3
March 28, 2008
- Letrozole Cuts Risk Of Breast Cancer Recurrence Even After Tamoxifen Use
- Recurrent Low-Grade Serous Carcinoma Less Responsive To Chemotherapy
- BMI May Be Prognostic Tool For Types Of Breast Cancer
- Postoperative Chemo Doesn’t Improve Survival, Study Finds
- Risks Of Long-Term HRT Outweigh Benefits, WHI Finds
- Cause Of Allergic Reaction To Cetuximab Found
- NCI Cooperative Group, Cancer Center Trials Listed